Lilly Delivers Strong Third-Quart...(nciliations below for furtherdetail. ...),Health

Q4 Earnings per Share Reconciliation

------------------------------------

Q4 2007 Q4 2006

Expectations Results % Growth

------------ ------- --------

E.P.S. (reported) $.83 to $.88 $.12 NM

Eliminate estimated in-process

research & development charge

associated with MacroGenics

in-licensing .03 -

Eliminate product liability

charge - .42

Eliminate asset impairments,

restructuring and other special

charges - .31

Include pro forma as if the ICOS

acquisition was completed on

January 1, 2006 - (.03)

------------ -----

E.P.S. (pro forma adjusted) $.86 to $.91 $.82 5% to 11%

------------ -----

Full-Year Earnings per Share Reconciliation

--------------------------------------------

2007 2006

Expectations Results % Growth

------------ ------- ---------

E.P.S. (reported) $2.76 to $2.81 $2.45 13% to 15%

Eliminate estimated in-process

research & development charge

associated with MacroGenics

in-licensing .03 -

Eliminate product liability charge - .42

Eliminate asset impairments and

restructuring charges associated

with previously announced

manufacturing decisions
'/>"/>